Multiple myeloma management requires a balance between maximizing survival, minimizing adverse events to therapy, and monitoring disease progression. While previous work has proposed data-driven models for individual tasks, these approaches fail to provide a…
Continue Reading
Digital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson’s disease (PD), by allowing objective and recurrent measurement of symptoms and signs collected in the…
Continue Reading
Gait impairments are among the most common and disabling symptoms of Parkinson’s disease and worsen as the disease progresses. Early detection and diagnosis of subtype-specific gait deficits, as well as progression monitoring, can help…
Continue Reading
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification…
Continue Reading
Wearable sensor technologies are becoming increasingly relevant in health research, particularly in the context of chronic disease management. They generate real-time health data that can be translated into digital biomarkers, which can provide insights…
Continue Reading
Canary Speech, maker of AI-enabled speech analysis software, announced it scored $13 million in Series A funding. Cortes Capital (Love’s Private Equity) led the round, with participation from SMK (Japan), Hackensack Meridian Health and Sorenson…
Continue Reading
Massachusetts Institute of Technology (MIT) announced it is partnering with wearable maker Movano Health to use its Evie Ring’s continuous health monitoring capabilities to study COVID and chronic Lyme disease. The ring will be used…
Continue Reading
What You Should Know:
– Canary Speech, Inc. (Canary), a pioneer in AI-powered voice biomarker technology, announced today it has closed a $13M Series A funding round.
– The round was led by Cortes Capital, LLC…
Continue Reading
What You Should Know:
– OncoHost, a company pioneering personalized medicine approaches for better patient outcomes, announced a collaborative research study with Dana-Farber Cancer Institute, a leading cancer treatment and research center.
– The project aims…
Continue Reading
We have developed a digital twin-based CKD identification and prediction model that leverages generalized metabolic fluxes (GMF) for patients with Type 2 Diabetes Mellitus (T2DM). GMF digital twins utilized basic clinical and physiological biomarkers…
Continue Reading
